As we have previously reported, research has shown that several incretin mimetic pharmaceuticals, such as Byetta, Januvia/Janumet and Victoza, may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas.
Doctors have expressed concern about these drugs and their connection between pancreatitis, pancreatic cancer and thyroid cancer. The Food and Drug Administration (“FDA”) is meeting with members at the National Institutes of Health this month, June 2013, to discuss the risks associated with these medications. Reuters reports that the manufacturers of these drugs agree that an independent study is needed to better understand the link between the medicine and pancreatic cancer. The American Diabetes Association has also expressed concern with the link between these drugs and pancreatic cancer and agrees that an independent study is needed.
If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.